NJII Launches Cell and Gene Therapy Manufacturing Center
The center will be located at NJIT’s Life Sciences and Engineering center and will feature two good manufacturing practices suites that are expected to be completed and operational during the summer of 2020.
The Biopharma Division of the New Jersey Innovation Institute (NJII), a New Jersey Institute of Technology (NJIT) corporation, announced on May 4, 2020 that it is launching BioCentriq, a cell and gene therapy production and manufacturing center in Newark, NJ.
According to a company press release, the center will be located at NJIT’s Life Sciences and Engineering center and will feature two good manufacturing practices suites that are expected to be completed and operational during the summer of 2020.
“BioCentriq will help bring innovative and novel therapies to clinical trials, providing a venue for established companies and start-ups alike. It is also a unique training ground for the workforce of the future,” said Dr. Haro Hartounian, senior vice-president and general manager of Biopharma at NJII, in the press release. “We are grateful to all our partners who have supported us financially and with in-kind donations of equipment and supplies, as well as the industry leaders who serve on our advisory board and lend us their expertise.”
Source: NJII
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.
